Skip to content

Zevra Therapeutics, Inc. ZVRA Discount and rebate liabilities, less current portion

Discount and rebate liabilities, less current portion at other companies

WD-40 Company logo
WD-40 CompanyWDFC
$11.8M-20.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$45.49M+48.0%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$69.88M
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$317.69M-2.1%
FMC Corporation logo
FMC CorporationFMC
$480M-15.8%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$38.42M+69.7%

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$782.09M+58.2%
Enterprise value$687.64M+32.5%
P/E6.3×
P/S6.4×-5.8×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity-1.5×
Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept zvra:DiscountAndRebateLiabilityNoncurrent.

The official record: Zevra Therapeutics, Inc.’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s discount and rebate liabilities, less current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s discount and rebate liabilities, less current portion?
Zevra Therapeutics, Inc. (ZVRA) reported discount and rebate liabilities, less current portion of $9.69M in Q4 2025.
What does discount and rebate liabilities, less current portion mean?
This represents the long-term portion of estimated obligations for rebates, discounts, and other pricing concessions that are not expected to be settled within the next twelve months. It captures multi-year contractual commitments or long-term government program obligations related to product sales. This metric is critical for assessing the long-term gross-to-net revenue impact and the sustainability of commercial pricing strategies.